Carcinoid neuroendocrine cancers are relatively rare malignancies distinguished by small, slow growing tumors which affect the neuroendocrine system. These tumors typically originate in the gastro-intestinal tract, but sometimes arise in the lungs or other organs. Incidence is around 4 persons in 100,000 - but in many parts of the world the disease is under-diagnosed.
A variety of excellent treatment options are available, most of which target specific peptide receptors on the tumor cells. Among the best known treatments are Octreotide, Lanreotide and similar hormonal treatments, which provide symptomatic relief and have anti-proliferative benefits. Other newer therapies use these drugs in combination with radioisotopes, as a targeted radiation treatment.
This is an unmoderated forum for patients, caregivers, researchers, and physicians to discuss the clinical and nonclinical aspects of Carcinoid neuroendocrine cancer. Please refer to the house rules before you post any commercial, copyrighted, political or off-topic material.
To access this forum, click on the "Subscribe or Unsubscribe" link, enter a name (or nickname), provide a valid email address, select the type of subscription (Index HTML format is recommended), submit the form and acknowledge the email sent to you for verification. For more information, click on the 'help' button (a green question mark in the upper-right corner of this page), or send email to the list owners.
Quick links: [house rules], [settings], [email list managers], [CCF archives] and [unsubscribe]